循环肿瘤DNA可区分转移性黑色素瘤免疫治疗中的假性进展
该探索性生物标志物研究纳入125例接受PD-1抗体单药或联合伊匹木单抗的转移性黑色素瘤患者,分析基线与治疗前12周循环肿瘤DNA(ctDNA)的BRAF/NRAS突变。结果显示,ctDNA特征可准确区分假性进展与真性进展,并预测长期生存。
要点
- ctDNA预测假性进展敏感性90%(95%CI 68%-99%),特异性100%(95%CI 60%-100%)。
- 定期ctDNA检测有潜力作为预测长期应答与生存的生物标志物。
核心结论
- ctDNA特征可准确区分PD-1抗体治疗黑色素瘤患者的假性进展与真性进展。
- 治疗期间定期ctDNA检测反映肿瘤生物学,有潜力预测长期应答与生存。
研究设计与样本
- 探索性生物标志物研究,2014年7月3日至2016年5月24日纳入125例接受PD-1抗体单药或联合伊匹木单抗的黑色素瘤患者。
- 前瞻性采集基线与治疗前12周血浆样本,分析循环BRAF和NRAS突变。
- 假性进展定义为下次影像评估未确认的放射学进展。
主要发现
- 125例中29例(23.2%)按RECIST出现进展,其中9例(31%)为假性进展,20例(69%)为真性进展。
- 9例确认假性进展患者全部具有有利ctDNA特征。
- 真性进展患者中除2例外均具有不利ctDNA特征。
- 中位随访110周时,9例假性进展患者中7例(78%)存活。
关键数值与推荐
- ctDNA预测假性进展的敏感性为90%(95%CI 68%-99%),特异性为100%(95%CI 60%-100%)。
- 有利ctDNA特征定义为基线ctDNA不可测或基线可测后下降>10倍;不利特征定义为基线可测且稳定或升高。
- 假性进展回顾性定义为放射学进展但下次影像评估未确认进展。
临床怎么用
- 对PD-1抗体治疗后出现影像学进展的黑色素瘤患者,可结合治疗前12周ctDNA动态辅助鉴别假性进展与真性进展。
- ctDNA有利特征提示假性进展可能及较好生存,支持继续治疗而非过早停药。
局限性
- 探索性生物标志物研究,样本量有限。
- 假性进展定义基于回顾性影像评估。
- 假性进展患者仅9例,置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Longitudinal circulating tumor DNA (ctDNA) has been shown to predict response and survival in patients with metastatic melanoma treated with anti-programmed cell death 1 (PD-1) antibodies. Pseudoprogression, defined as radiologic finding of disease progression prior to response, has been a challenge to clinicians. OBJECTIVE: To establish whether ctDNA at baseline and up to week 12 of treatment can differentiate between the radiologic findings of pseudoprogression and true progression in patients with metastatic melanoma. DESIGN, SETTING, AND PARTICIPANTS: This explorative biomarker study examined circulating BRAF and NRAS mutations in a cohort of 125 patients with melanoma receiving PD-1 antibodies alone or in combination with ipilimumab between July 3, 2014, and May 24, 2016. Pseudoprogression was defined retrospectively as radiologic progression not confirmed as progressive disease at the next radiologic assessment. Plasma samples of ctDNA at baseline and while receiving treatment were taken for analysis prospectively over the first 12 weeks of treatment. Favorable ctDNA profile (undetectable ctDNA at baseline or detectable ctDNA at baseline followed by >10-fold decrease) and unfavorable ctDNA profile (detectable ctDNA at baseline that remained stable or increased) were correlated with response and prognosis. MAIN OUTCOMES AND MEASURES: Early differentiation of pseudoprogression from true progression using longitudinal ctDNA profile. RESULTS: According to guidelines by Response Evaluation Criteria in Solid Tumors (RECIST), progressive disease occurred in 29 of the 125 patients (23.2%). Of the 29 patients, 17 (59%) were 65 years or younger, 18 (62%) were men, 9 (31%) had pseudoprogression, and 20 (69%) had true progression. Of the 9 patients (7%) with confirmed pseudoprogression, all patients had a favorable ctDNA profile. At a median follow-up of 110 weeks, 7 of 9 patients (78%) were alive. All but 2 patients with true progression had an unfavorable ctDNA profile. Sensitivity of ctDNA for predicting pseudoprogression was 90% (95% CI, 68%-99%) and specificity was 100% (95% CI, 60%-100%). The 1-year survival for patients with RECIST-defined progressive disease and favorable ctDNA was 82% vs 39% for unfavorable ctDNA (hazard ratio [HR], 4.8; 95% CI, 1.6-14.3; P = .02). Overall survival was longer in patients with a partial response (54 of 125 patients [43%]) compared with patients with progressive disease and a favorable ctDNA profile (11 of 125 patients [9%]; HR, 0.09; 95% CI, 0.01-0.80; P < .01). CONCLUSIONS AND RELEVANCE: The results demonstrate that ctDNA profiles can accurately differentiate pseudoprogression from true progression of disease in patients with melanoma treated with PD-1 antibodies. Results of this blood test performed at regular intervals during systemic treatment reflect tumor biology and have potential as a powerful biomarker to predict long-term response and survival.
引用
- Lee JH, Long GV, Menzies AM, et al. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol. 2018. PMID: 29423503. doi:10.1001/jamaoncol.2017.5332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。